Grand Rapids, MI (July 31, 2019): Tetra Discovery Partners, a clinical-stage biotechnology company, today announced the company’s name change to Tetra Therapeutics. The name change reflects the company’s transition from a company focused on discovery research to one with multiple clinical-stage programs aimed at treating conditions that impair thought and human brain function.
“Tetra was founded in 2011 with the goal of developing a portfolio of therapeutics aimed at treating cognitive impairment and memory loss by improving how the brain processes and stores information,” said Mark Gurney, Ph.D., Chairman and Chief Executive Officer. “Thanks to our investors, our partners, and the hard work of our team, we are today a clinical stage company with our first drug candidate, BPN14770, undergoing human testing in both Alzheimer’s disease and Fragile X Syndrome, the most common genetic form of autism.”
Since 2011 Tetra has raised $72 million through a public-private partnership model with the National Institutes of Health, the FRAXA Research Foundation for Fragile X Syndrome, the Alzheimer’s Drug Discovery Foundation, and private and strategic investors.
BPN14770 was developed through a cooperative research agreement with the NIH Blueprint Neurotherapeutics Program. BPN14770 is designed to selectively modulate PDE4D, an enzyme that plays an important role in cognition and memory formation. Tetra is conducting the PICASSO AD Phase 2 study of BPN14770 in patients diagnosed with early Alzheimer’s disease at multiple research centers across the United States, and a Phase 2 study in patients with Fragile X Syndrome at Rush University Medical Center in Chicago. The company plans to announce top-line results of both trials in 2020. In December 2018, Tetra partnered with Shionogi & Co., Ltd. for the development of BPN14770 in Japan and other Asian countries. In addition, the company is developing multiple PET tracers to permit the imaging of PDE4 enzymes in the brain.
To inquire about participation in BPN14770 clinical trials, visit the tetratherapeutics.com website.
Tetra Therapeutics is a clinical-stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X Syndrome, Alzheimer’s disease, traumatic brain injury, and other brain disorders. Tetra uses structure-guided drug design to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4 (PDE4), an enzyme family that plays key roles in memory formation, learning, neuroinflammation, and traumatic brain injury. BPN14770 was developed through a cooperative research agreement with the Blueprint Neurotherapeutics Program of the National Institutes of Health with funding from the National Institute on Aging, National Institute on Neurological Disorders and Stroke, the National Institute of Mental Health, the FRAXA Research Foundation and the Alzheimer’s Drug Discovery Foundation. Tetra Discovery Partners is headquartered in Grand Rapids, Michigan. For more information, please visit the company’s website at tetratherapeutics.com.
Certain other statements made throughout this press release that are not historical facts contain forward-looking statements regarding the company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
Tetra Therapeutics Contacts:
Mark Gurney, Ph.D., Chief Executive Officer